Pulse Biosciences (NASDAQ:PLSE) is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Co
Pulse Biosciences (NASDAQ:PLSE) reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment.
Chief Executive Officer and Co-Chairman Paul LaViolette said the company’
Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program.
On the company’s earnings call, Co-Chairman and C
Pulse Biosciences reported a Q2 2025 net loss of $0.28 per share, slightly wider than estimates, with no revenue. The company advances its nsPFA tech in clinical trials, focusing on atrial fibrillation and thyroid treatments. Cash reserves stand at $106.3M.
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-than-expected June inflation data and potential interest rate cuts.
